Learn about an exciting new mRNA vaccine that could prevent a wide variety of allergies, and even help those with asthma and celiac disease.

Dr. Scott Rivkees, predecessor to Florida Surgeon General Dr. Joseph Ladapo, says his successor's latest statements are 'part of an organized strategy to undermine vaccinations in Florida.' ...

The vaccination campaign comes as COVID-19 cases in people going to emergency or urgent care for respiratory symptoms have increased. About 10 per cent of tests were positive for the week ending Sept.

As the country’s chief health advocate, Robert F. Kennedy Jr. wields major influence over the public health of Americans. Critics argue that Kennedy’s collective efforts have sown confusion and are ...

The amount of any given protein in a cell has to be controlled to keep its levels within a range required for healthy functions. This is especially important for proteins that are known to group ...

Now a new study has outlined practical strategies experts say can help improve childhood vaccine uptake in Australia. It builds on a national 2024 survey that showed the surprising reasons for the ...

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the best strategy now.

The symptoms of XFG closely resemble those of other COVID variants, Weber said, and may include: Yes. Studies have shown rapid antigen tests can detect a variety of COVID variants, including XFG, ...

Yet not all large-scale research into mRNA vaccines in the United States is being dismantled. Nature has learnt that, even as the US Department of Health and Human Services (HHS) — led by vaccine ...

This is the time of year when updated boosters for COVID-19 are typically available. But this year has been anything but typical.

People are still debating whether the mRNA from COVID-19 vaccines remains in the body longer than it should. Some say it lingers and causes harm, others say that idea just doesn’t hold up. A new ...

Moderna's 2025-2026 mNEXSPIKE showed strong immune response and safety in Phase 4 trials, reinforcing FDA approval for the LP.8.1-targeting formula.